{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:54:37Z","timestamp":1760230477082,"version":"build-2065373602"},"reference-count":49,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>After emergency authorization, different COVID-19 vaccines were administered across Mexico in 2021, including mRNA, viral vector, and inactivated platform vaccines. In the state of Baja-California, 3,516,394 doses were administered, and 2285 adverse events (AE) were registered in the epidemiological surveillance system in 2021. Incidence rates per 100,000 doses were calculated for total, mild (local and systemic), and severe AE for each vaccine. Symptoms were compared between mRNA and viral vector\/inactivated virus vaccines. The overall incidence rate for all AE was 64.98 per 100,000 administered doses; 79.05 AE per 100,000 doses for mRNA vaccines; and 56.9 AE per 100,000 doses for viral vector\/inactivated virus vaccine platforms. AE were at least five times higher in recipients of the AstraZeneca vaccine from the Serum Institute of India (AZ from SII). Local injection site symptoms were more common in mRNA vaccines while systemic were more prevalent in viral vector\/inactivated virus vaccines. Severe AE rates were similar across all administered vaccines (0.72\u20131.61 AE per 100,000 doses), except for AZ from SII, which documented 12.6 AE per 100,000 doses. Among 32 hospitalized severe cases, 28 (87.5%) were discharged. Guillain\u2013Barr\u00e9 Syndrome was the most common serious AE reported (n = 7). Adverse events rates differed among vaccine manufacturers but were consistent with clinical trials and population-based reports in the literature.<\/jats:p>","DOI":"10.3390\/vaccines10081196","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:41:16Z","timestamp":1659058876000},"page":"1196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico"],"prefix":"10.3390","volume":"10","author":[{"given":"Cesar A.","family":"Mendez-Lizarraga","sequence":"first","affiliation":[{"name":"Departamento de Epidemiolog\u00eda, Secretar\u00eda de Salud de Baja California, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2466-4920","authenticated-orcid":false,"given":"Enrique","family":"Chacon-Cruz","sequence":"additional","affiliation":[{"name":"Departamento de Infectolog\u00eda Pedi\u00e1trica, Hospital General de Tijuana, Tijuana 22000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8013-5014","authenticated-orcid":false,"given":"Ricardo","family":"Carrillo-Meza","sequence":"additional","affiliation":[{"name":"Unidad Ciencias de la Salud, Universidad Aut\u00f3noma de Baja California, Mexicali 21376, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00e9stor Sa\u00fal","family":"Hern\u00e1ndez-Mil\u00e1n","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n General de Servicios de Salud del Estado de Baja California, Secretar\u00eda de Salud de Baja California, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie C.","family":"Inustroza-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Departamento de Epidemiolog\u00eda, Secretar\u00eda de Salud de Baja California, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-5122","authenticated-orcid":false,"given":"Diego F.","family":"Ovalle-Marroqu\u00edn","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Ense\u00f1anza e Investigaci\u00f3n, Secretar\u00eda de Salud de Baja California, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Ren\u00e9","family":"Machado-Contreras","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Baja California, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Ceballos Zu\u00f1iga","sequence":"additional","affiliation":[{"name":"Departamento de Medicina Interna, Hospital General de Mexicali, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Bejarano-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Laboratorio Estatal de Salud P\u00fablica, Secretar\u00eda de Salud de Baja California, Mexicali 21010, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cipriano","family":"Aguilar-Aguayo","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n General de Servicios de Salud del Estado de Baja California, Secretar\u00eda de Salud de Baja California, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Medina-Amarillas","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n General de Servicios de Salud del Estado de Baja California, Secretar\u00eda de Salud de Baja California, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santa Elizabeth","family":"Ceballos-Liceaga","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n General de Epidemiolog\u00eda, Secretar\u00eda de Salud, Gobierno de M\u00e9xico, Ciudad de M\u00e9xico 01480, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5374-3906","authenticated-orcid":false,"given":"Oscar E.","family":"Zazueta","sequence":"additional","affiliation":[{"name":"Departamento de Epidemiolog\u00eda, Secretar\u00eda de Salud de Baja California, Mexicali 21000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_2","unstructured":"World Health Organization (2022, May 05). Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV), Available online: https:\/\/www.who.int\/news\/item\/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)."},{"key":"ref_3","unstructured":"World Health Organization (2022, May 05). Timeline: WHO\u2019s COVID-19 Response, Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/interactive-timeline#!."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: From SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chilamakuri, R., and Agarwal, S. (2021). COVID-19: Characteristics and Therapeutics. Cells, 10.","DOI":"10.3390\/cells10020206"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Rusia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"ref_8","unstructured":"World Health Organization (2022, May 05). COVID-19 Vaccine Tracker and Landscape, Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_9","unstructured":"Secretar\u00eda de Econom\u00eda (2022, March 03). DataM\u00e9xico BETA, Available online: https:\/\/datamexico.org\/en\/profile\/geo\/baja-california-bc?PEFYears3=2019&fdiSelectorButton1=genericInvestment&fdiTimeSelector=Year&foreignYearSelector1=2019&foreignYearSelector2=2019&timeNetTradeSelector=Year&fdiYearSelector=2019."},{"key":"ref_10","unstructured":"Bureau of Transportation Statistics (2022, March 01). Border Crossing\/Entry Data, Available online: https:\/\/www.bts.gov\/browse-statistical-products-and-data\/border-crossing-data\/border-crossingentry-data."},{"key":"ref_11","unstructured":"Secretar\u00eda de Salud (2022, May 05). Pol\u00edtica Nacional de Vacunaci\u00f3n contra el Virus SARS-CoV-2, para la prevenci\u00f3n de la COVID-19 En M\u00e9xico, Available online: https:\/\/coronavirus.gob.mx\/wp-content\/uploads\/2021\/04\/28Abr2021_13h00_PNVx_COVID_19.pdf."},{"key":"ref_12","unstructured":"Comisi\u00f3n Federal para la Protecci\u00f3n Contra Riesgos Sanitarios (2022, May 05). La COFEPRIS Otorga Autorizaci\u00f3n Para Uso de Emergencia a Vacuna para Prevenir la Enfermedad por Coronavirus (COVID-19), Available online: https:\/\/www.gob.mx\/cofepris\/articulos\/la-cofepris-otorga-autorizacion-para-uso-de-emergencia-a-vacuna-para-prevenir-la-enfermedad-por-coronavirus-covid-19."},{"key":"ref_13","unstructured":"Comisi\u00f3n Federal Para la Protecci\u00f3n Contra Riesgos Sanitarios (2022, May 05). Vacunas COVID-19 Autorizadas, Available online: https:\/\/www.gob.mx\/cofepris\/acciones-y-programas\/vacunas-covid-19-autorizadas."},{"key":"ref_14","unstructured":"(2022, May 05). Direcci\u00f3n General de Epidemiolog\u00eda, Direcci\u00f3n de Vigilancia Epidemiolog\u00eda de Enfermedades Transmisibles. Manual de Procedimientos Estandarizados Para la Vigilancia Epidemiol\u00f3gica de Eventos Supuestamente Atribuibles a la Vacunaci\u00f3n o Inmunizaci\u00f3n (ESAVI). Versi\u00f3n 2021. Available online: https:\/\/epidemiologia.salud.gob.mx\/gobmx\/salud\/documentos\/manuales\/42_Manual_ESAVI.pdf."},{"key":"ref_15","unstructured":"(2022, May 05). Direcci\u00f3n General de Epidemiolog\u00eda. Reporte ESAVI COVID-19 Marzo. Available online: https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/718427\/REPORTEESAVIDVEETMARZO2022.pdf."},{"key":"ref_16","unstructured":"(2022, May 20). Border COVID-19 Vaccination Plan with U.S.-Donated Shots Starts in Baja-California. Available online: https:\/\/www.latimes.com\/california\/story\/2021-06-19\/border-covid-19-vaccination-plan-us-donated-shots-baja-california."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ana.26339","article-title":"Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS","volume":"91","author":"Frontera","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"680","DOI":"10.15585\/mmwr.mm7018e2","article-title":"Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine\u2014United States, March\u2013April 2021","volume":"70","author":"Shay","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"729251","DOI":"10.3389\/fimmu.2021.729251","article-title":"COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis","volume":"12","author":"Bilotta","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117607","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Bahmanyar","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_21","unstructured":"Pan American Health Organization (2022, May 05). Consultation Document for Case Definitions. Available online: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/55721\/PAHOHSSMTCOVID-19210017_eng.pdf?sequence=1&isAllowed=y."},{"key":"ref_22","first-page":"3307","article-title":"Bias, Precision and Timeliness of Historical (Background) Rate Comparison Methods for Vaccine Safety Monitoring: An Empirical Multi-Database Analysis","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3389\/fpubh.2021.756633","article-title":"Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States","volume":"9","author":"Montano","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jcpa.2007.04.012","article-title":"Mechanisms underlying adverse reactions to vaccines","volume":"137","author":"Siegrist","year":"2007","journal-title":"J. Comp. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines: Knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"Heinz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13037-021-00291-9","article-title":"The safety of Covid-19 mRNA vaccines: A review","volume":"15","author":"Anand","year":"2021","journal-title":"Patient Saf. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41569-021-00662-w","article-title":"Myocarditis after COVID-19 mRNA vaccination: Clinical observations and potential mechanisms","volume":"19","author":"Heymans","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dietmann, A., Ripellino, P., Humm, A.M., Hundsberger, T., Schreiner, B., Th\u00e9audin, M., and Scheidegger, O. (2022). Hot Topics on COVID-19 and Its Possible Association with Guillain-Barr\u00e9 Syndrome. Clin. Transl. Neurosci., 6.","DOI":"10.3390\/ctn6010007"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Khalil, L., Leary, M., Rouphael, N., Ofotokun, I., Rebolledo, P.A., and Wiley, Z. (2022). Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. Vaccines, 10.","DOI":"10.3390\/vaccines10020290"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101218","DOI":"10.1016\/j.eclinm.2021.101218","article-title":"A phase 2\/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India","volume":"42","author":"Kulkarni","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108786","DOI":"10.1016\/j.clim.2021.108786","article-title":"Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study","volume":"229","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"834744","DOI":"10.3389\/fpubh.2022.834744","article-title":"Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population","volume":"10","author":"Moll","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13223-021-00613-7","article-title":"Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: A systematic review and meta-analysis","volume":"17","author":"Alhumaid","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Eroglu, B., Nuwarda, R.F., Ramzan, I., and Kayser, V. (2022). A Narrative Review of COVID-19 Vaccines. Vaccines, 10.","DOI":"10.3390\/vaccines10010062"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"key":"ref_41","unstructured":"The Medicines and Healthcare Products Regulatory Agency (MHRA) (2022, July 19). Coronavirus Vaccine\u2014Summary of Yellow Card Reporting, Available online: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting."},{"key":"ref_42","unstructured":"Instituto de Salud P\u00fablica, Ministerio de Salud, Gobierno de Chile (2022, July 19). Noveno Informe Estad\u00edstico \u201cESAVI Asociados a la Administraci\u00f3n de Vacunas SARS-CoV-2 en Chile en Personas Desde los 18 a\u00f1os\u201d, Available online: ispch.cl\/wp-content\/uploads\/2022\/05\/9\u00b0-Informe-Estadistico-Poblacion-Mayor-de-18-anos-VF3.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.18231\/j.ijcaap.2022.017","article-title":"Pattern of adverse effects following ChAdOx1 nCoV-19 COVISHIELD vaccination in adults in tertiary healthcare institution in North India: A retrospective observational study","volume":"7","author":"Gautam","year":"2022","journal-title":"IJCAP"},{"key":"ref_44","unstructured":"Food and Drug Administration (2022, May 05). Emergency Use Authorization for Vaccines to Prevent COVID-19, Available online: https:\/\/www.fda.gov\/media\/142749\/download."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40264-022-01151-w","article-title":"Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands","volume":"45","author":"Kant","year":"2022","journal-title":"Drug Safety"},{"key":"ref_46","unstructured":"AstraZeneca (2022, July 18). Serum Institute of India Obtains Emergency Use Authorization in India for AstraZeneca\u2019s COVID-19 Vaccine. Available online: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/serum-institute-of-india-obtains-emergency-use-authorisation-in-india-for-astrazenecas-covid-19-vaccine.html."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"ref_48","unstructured":"(2022, May 20). COVID-19 Vaccines, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines."},{"key":"ref_49","unstructured":"(2022, May 20). Drug and Vaccine Authorizations for COVID-19: List of Authorized Drugs, Vaccines and Expanded Indications. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/authorization\/list-drugs.html#wb-auto-4."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:57:32Z","timestamp":1760140652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["vaccines10081196"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10081196","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,7,27]]}}}